GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting ...

iTeos Therapeutics anticipates this year an interim readout from its Phase III GALAXIES Lung-301 trial of its anti-TIGIT antibody belrestotug in combination with GlaxoSmithKline's anti-PD-1 monoclonal ...

Riot Games categorizes them into four classes, each with a distinct role, to make it easier for players to make a balanced team from the roster. Duelists are self-sufficient fraggers. They’re ...

Topping the range for the time being is the AMG E53, a six-cylinder PHEV. In other regions, there's an E450 petrol as well, but that isn't offered in the UK for the time being - and is unlikely to ...

The main drug in FDA-approved treatment is called dostarlimab-gxly (brand name Jemperli). It is an immune checkpoint inhibitor ... with a much greater response to the check-point inhibitor class of ...

The latest generation of the venerable (try 45 years of consistent production) Geländewagen/G-Class/G-Wagen. Always a legend, a total overhaul back in 2018 saw it ...

MANILA, Philippines — Classes in public elementary and high schools resumed yesterday after almost two weeks of holiday break. While most college and university students are still enjoying their ...

In another press release, GSK announced that the CHMP has recommended expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary advanced or recurrent ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with annual revenues of $41.86 billion and an impressive gross profit margin of 72.39%, has received Breakthrough Therapy Designation from ...

The safety profile of the combined treatment was consistent with the known profiles of the individual agents. In the United States, Jemperli's label was already expanded in August 2024 to include all ...